4/8
09:11 am
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at Stifel Nicolaus from $71.00 to $73.00. They now have a "buy" rating on the stock.
Medium
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at Stifel Nicolaus from $71.00 to $73.00. They now have a "buy" rating on the stock.
4/2
02:34 pm
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its price target lowered by analysts at Morgan Stanley from $75.00 to $40.00. They now have an "equal weight" rating on the stock.
Low
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its price target lowered by analysts at Morgan Stanley from $75.00 to $40.00. They now have an "equal weight" rating on the stock.
4/2
01:53 pm
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its price target lowered by analysts at BMO Capital Markets from $80.00 to $50.00. They now have an "outperform" rating on the stock.
Low
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its price target lowered by analysts at BMO Capital Markets from $80.00 to $50.00. They now have an "outperform" rating on the stock.
4/2
09:02 am
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its price target lowered by analysts at Stifel Nicolaus from $104.00 to $71.00. They now have a "buy" rating on the stock.
Medium
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its price target lowered by analysts at Stifel Nicolaus from $104.00 to $71.00. They now have a "buy" rating on the stock.
4/1
03:32 pm
iron
Attention Disc Medicine, Inc. Investors: Company Investigated by the Portnoy Law Firm
Medium
Report
Attention Disc Medicine, Inc. Investors: Company Investigated by the Portnoy Law Firm
4/1
01:38 pm
iron
Investigation of Disc Medicine, Inc. (IRON) Announced by Holzer & Holzer, LLC
Medium
Report
Investigation of Disc Medicine, Inc. (IRON) Announced by Holzer & Holzer, LLC
4/1
01:22 pm
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $43.00 price target on the stock, down previously from $84.00.
Medium
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $43.00 price target on the stock, down previously from $84.00.
4/1
11:03 am
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $40.00 price target on the stock.
High
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $40.00 price target on the stock.
4/1
10:15 am
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
High
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
4/1
08:00 am
iron
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
High
Report
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
3/22
11:19 am
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
Medium
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
3/21
11:09 pm
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $84.00 price target on the stock, up previously from $79.00.
Medium
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $84.00 price target on the stock, up previously from $79.00.
3/21
08:00 am
iron
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Medium
Report
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
3/6
04:30 pm
iron
Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
Medium
Report
Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
2/29
08:16 am
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at BMO Capital Markets from $70.00 to $80.00. They now have an "outperform" rating on the stock.
Medium
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at BMO Capital Markets from $70.00 to $80.00. They now have an "outperform" rating on the stock.
2/26
08:30 am
iron
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer
Low
Report
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer
2/20
08:30 am
iron
Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Low
Report
Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
2/9
09:00 am
iron
Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera
Low
Report
Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera
2/7
08:00 am
iron
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer
Low
Report
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer